Skip to main content
. Author manuscript; available in PMC: 2014 Feb 1.
Published in final edited form as: J Thorac Oncol. 2013 Feb;8(2):179–184. doi: 10.1097/JTO.0b013e3182779d18

Figure 3.

Figure 3

Survival from date of advanced disease by EGFR genotype. Lung cancers with exon 20 insertions have a median survival of 16.5 months, shorter than the median survival of 33.0 months in those with common EGFR mutations (A, p=0.06) but similar to the median survival of 20.0 months in EGFR wild-type cancers (B, p=0.60).